4Q-25 Quarterly Results 4Q-25 Revenue of $642M, 0% y/y 4Q-25 Net loss per share of $(0.14)(1) 4Q-25 Adj. EBITDA(2) of $83.8M, 12% y/y FY-26 Revenue outlook range of $2,470M to $2,587M Cautionary Note 2 • This presentation contains, and the officers of Teladoc Health, Inc. (the "Company" or "Teladoc Health") may make, "forward-looking" statements that are based on management's beliefs and assumptions and on information currently available to management. These forward-looking statements include, without limit ...

投资人跟创业者接触的时候，为了节省时间，通常会向创业者索要商业计划书。一份好的商业计划书不仅可以让你的创业之路更加的明晰，还能让你更容 易打动投资人。 首先，它是对创业项目的一次全面梳理和深度思考过程。在撰写商业计划书时，创业者需要详细分析市场环境、目标客户群体、竞争对手情况等，这有助 于创业者更清晰地了解自身项目所处的位置，明确优势与不足，从而制定出更具针对性和可行性的发展战略。 其次，商业计划书是创业者与投资人沟通的重要桥梁。一份逻辑清晰、内容详实的商业计划书能够准确地向投资人传达创业项目的核心价值、盈利模式以 及发展潜力等关键信息，让投资人在短时间内对项目有一个较为全面的认识，增加投资人进一步了解项目的兴趣，为后续的融资谈判奠定良好的基础。 要素二：产品和服务 第二部分要开宗明义，写清楚你们公司将来要干什么，提供什么样的产品和服务，解决什么问题。很多产品不只解决一个问题，在投资计划书中，要选择 产品的核心特点和优势。具体内容可以包括：产品看起来是什么样子的，如何使用，其客户价值如何。 复杂、笼统和虚幻，是不少计划书存在的普遍问题。其中，大量的篇幅不是在定量、有逻辑地描述想法，而是在堆砌对这些想法的溢美之 ...

Core Insights - The company is expected to report revenue of $16.15 billion for the current quarter, with a growth rate of 14.88%, and $16.81 billion for the next quarter, with a growth rate of 18.97% [2][4] - Gross margin is anticipated to be 70.36% for the current quarter and 69.55% for the next quarter [3] Financial Performance - Deferred revenue is projected to be $8.464 billion, showing a year-over-year growth of 5.01% [2] - Hardware revenue is expected to be $728 million, with a year-over-year decline of 3.70% [2] - Cloud services revenue is forecasted to reach $6.736 billion, reflecting a year-over-year growth of 26.83% [2] Regional Breakdown - Revenue from the Americas is expected to be $9.731 billion, with a year-over-year growth of 10.54% [2] - Asia Pacific revenue is projected at $1.800 billion, with a year-over-year growth of 3.35% [2] - EMEA revenue is anticipated to be $3.655 billion, with a year-over-year growth of 6.85% [2] Cost and Expenses - Cost of revenue is expected to be $1.104 billion, with a year-over-year growth of -1.07% [2] - Operating expenses are projected to be $5.403 billion, reflecting a year-over-year increase [2] Market Sentiment - Overall expectations for the company have been lowered multiple times, indicating a cautious market sentiment [4]

Core Viewpoint - Kinder Morgan's Q3 2025 earnings met estimates, with adjusted EPS of 29 cents and total revenues of $4.15 billion, indicating a positive performance trend [2][3]. Financial Performance - Adjusted EPS for Q3 2025 was 29 cents, matching the Zacks Consensus Estimate, and increased from 25 cents year-over-year [2]. - Total revenues reached $4.15 billion, surpassing the Zacks Consensus Estimate of $4.13 billion and up from $3.70 billion in the prior-year quarter [2]. Segmental Analysis - Natural Gas Pipelines segment saw adjusted EBDA rise to $1.4 billion from $1.27 billion year-over-year, driven by higher transported and gathering volumes [4]. - Product Pipelines segment's EBDA increased to $288 million from $276 million, attributed to higher diesel fuel volumes [5]. - Terminals segment generated EBDA of $274 million, up from $267 million, with liquids utilization at 94.6% [5]. - CO2 segment's EBDA fell to $136 million from $160 million year-over-year [6]. Operational Highlights - Operations and maintenance expenses totaled $786 million, slightly down from $790 million a year ago, while total operating costs rose to $3.08 billion from $2.68 billion [7]. - Kinder Morgan reported a project backlog of $9.3 billion, with a significant portion related to natural gas projects [7]. Balance Sheet - As of September 30, 2025, Kinder Morgan had $71 million in cash and cash equivalents, with long-term debt amounting to $31.3 billion [8]. Outlook - For the year, Kinder Morgan projected net income of $2.8 billion and estimated adjusted EPS of $1.27, with a net debt-to-adjusted EBITDA ratio expected at 3.8x by the end of 2025 [9]. - Recent estimates for the stock have trended upward, indicating a promising outlook [10][12].

Core Insights - Internal conflicts at xAI stem from disagreements between departing executives and Musk's close advisors regarding management style and the credibility of financial forecasts [1][2] - The company is experiencing significant executive turnover, raising concerns about its internal stability and future development as it invests heavily to compete with industry leaders like OpenAI [1][2] Management Dynamics - The management structure at xAI, characterized by Musk's unique approach, has led to confusion over responsibilities, with Musk retaining ultimate decision-making power while his advisors manage daily operations [2] - The involvement of Antonio Gracias from Valor Equity Partners indicates the seriousness of the internal disputes, although Musk's lawyer has denied claims of mediation [2] Financial Health and Pressures - Departing executives have expressed concerns that some of xAI's financial forecasts are unrealistic, especially in light of competitors like OpenAI and Anthropic having more paying customers [3] - xAI is investing heavily in infrastructure, including a large data center in Memphis, which has raised alarms among former executives and investors regarding financial sustainability [3] Financing Landscape - xAI has raised over $15 billion since its inception, with notable investors including Andreessen Horowitz and Fidelity, indicating a complex financing network [5] - Recent funding from SpaceX and potential investments from Tesla highlight the interconnectedness of Musk's companies, although there are concerns about xAI's ability to secure new debt financing due to restrictions from a recent $5 billion debt arrangement by Morgan Stanley [5]

Core Viewpoint - Bruker Corporation's recent earnings report indicates a decline in both adjusted earnings per share and revenues, raising concerns about future performance and prompting a downward revision of financial guidance for 2025 [2][10][11]. Financial Performance - Adjusted EPS for Q2 2025 was 32 cents, down 38.5% year over year, and missed the Zacks Consensus Estimate by 3.03% [2]. - Q2 revenues were $797.4 million, a decrease of 0.4% year over year, but slightly exceeded the Zacks Consensus Estimate by 0.11% [3]. - Organic revenues fell by 7% when excluding the positive impacts from acquisitions and foreign currency rates [3]. Geographic Revenue Breakdown - U.S. revenues decreased by 8.5% year over year to $222.9 million [4]. - European revenues fell by 1.2% to $272.5 million, while Asia Pacific revenues increased by 6.8% to $242.1 million [4]. Segment Analysis - Revenues in the BSI segment decreased by 0.3% to $733.2 million, with the BioSpin Group experiencing a 10.2% decline to $195.3 million due to weaker demand [5]. - CALID's revenues rose by 7.6% to $285.8 million, attributed to prior-year acquisitions, while NANO group revenues dipped slightly by 0.2% to $252.1 million [6]. - The BEST segment's revenues fell by 4.1% to $66.3 million, impacted by softness in the clinical MRI market [6]. Margin Performance - Gross profit declined by 6.9% to $357.9 million, with gross margin contracting by 315 basis points to 44.9% due to a 5.6% rise in the cost of revenues [7]. - Adjusted operating profit was $26.3 million, down 63% year over year, with adjusted operating margin contracting by 558 basis points to 3.2% [8]. Financial Position - Cash and cash equivalents at the end of Q2 2025 were $92 million, down from $184.2 million at the end of Q1 [9]. - Total long-term debt increased to $2.44 billion from $2.11 billion at the end of the previous quarter [9]. - Cumulative net cash used in operating activities was $127.5 million, compared to a cash inflow of $1.1 million during the same period last year [9]. 2025 Guidance - The company has revised its revenue guidance for 2025 to a range of $3.43-$3.50 billion, down from the previous estimate of $3.48-$3.55 billion, indicating a projected growth of 2% to 4% year over year [10][11]. - Adjusted EPS guidance for the year is now expected to be between $1.95 and $2.05, down from $2.40-$2.48 [11]. Estimate Trends - Consensus estimates have trended downward, with a significant shift of -38.69% noted in the past month [12]. VGM Scores - Bruker currently holds a poor Growth Score of F, a Momentum Score of F, and a Value Score of F, placing it in the fifth quintile for investment strategy [13]. Outlook - The downward trend in estimates suggests a challenging outlook for the stock, reflected in its Zacks Rank of 5 (Strong Sell) [14].